Login to Your Account

Biolinerx mobilized by FDA: Phase III BL-8040 challenge to Mozobil nearing

By Randy Osborne
Staff Writer

Wednesday, May 3, 2017

Biolinerx Ltd.'s chief business officer, David Malek, told BioWorld Today that the phase III trial with stem cell mobilizer BL-8040 likely will not be a head-to-head trial with approved Mozobil.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription